The pulmonary embolism after switching from letrozole to tamoxifen in a patient with breast cancer. A case report and literature review Case report
Article Sidebar
Published:
Mar 31, 2020
Keywords:
breast cancer, tamoxifen, pulmonary embolism, thromboprophylaxis
Main Article Content
Abstract
Women with breast cancer are affected by deep venous thrombosis and/or pulmonary embolism 3 times more often than the group of healthy women in the same age. Thrombosis can be the first manifestation of a malignant disease, but it can also result from hormonal therapy with aromatase inhibitors or tamoxifen which is used in cancer treatment. The necessary clinical problem to solve in this population is the issue of prophylactic antithrombotic treatment. In this paper we present a case of pulmonary embolism in the course of the breast cancer, which was associated with tamoxifen hormone therapy and inadequate thromboprophylaxis.
Downloads
Download data is not yet available.
Metrics
Metrics Loading ...
Article Details
How to Cite
1.
Tomaszewska A, Żach-Muzolf M, Grabysa R. The pulmonary embolism after switching from letrozole to tamoxifen in a patient with breast cancer. A case report and literature review. OncoReview [Internet]. 2020Mar.31 [cited 2024Nov.22];10(1(37):31-6. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/1081
Issue
Section
CARDIO-ONCOLOGY
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Tagalakis V, Patenaude V, Kahn SR et al. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med. 2013; 126(9): 832.e13-21.
2. Chew HK, Wun T, Harvey D et al. Incidence of Venous Thromboembolism and Its Effect on Survival Among Patients With Common Cancers. Arch Intern Med. 2006; 166(4): 458-64.
3. Brand JS, Hedayati E, Bhoo-Pathy N et al. Time-dependent risk and predictors of venous thromboembolism in breast cancer patients: A population-based cohort study. Cancer. 2017; 123(3): 468-75.
4. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005; 6: 401-10.
5. Braithwaite RS, Chlebowski RT, Lau J et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003; 18(11): 937-47.
6. Metzger Filho O, Giobbie-Hurder A, Mallon E et al. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. J Clin Oncol. 2015; 33(25): 2772-9.
7. Burstein HJ, Temin S, Anderson H et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014; 32(21): 2255-69.
8. Wojtukiewicz MZ, Sierko E. Zakrzepy a nowotwory. In: Windyga J,Pasierski T, Torbicki A (ed). Zakrzepy i zatory. Wyd. I. Wydawnictwo Lekarskie PZWL, Warszawa 2014: 85-105.
9. Wojtukiewicz MZ, Sierko E. Powikłania zakrzepowo zatorowe u chorych na nowotwory. In: Wojtukiewicz MZ, Deptała A (ed). Problemy hematologiczne u chorych na nowotwory. Wyd. I. Termedia, Poznań 2014; 225-50.
10. Cushman M, Costantino JP, Bovill EG et al. Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial. Br J Haematol. 2003; 120: 109-16.
11. Caine YG, Bauer KA, Barzegar S et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost. 1992; 68: 392-5.
12. de Valk-de Roo GW, Stehouwer CD, Meijer P et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol. 1999; 19: 2993-3000.
13. Kessler CM, Szymanski LM, Shamsipour Z et al. Estrogen replacement therapy and coagulation: relationship to lipid and lipoprotein changes. Obstet Gynecol. 1997; 89: 326-31.
14. Zoller B, Garcia de Frutos P, Dahlback B. Evaluation of the relationship between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease. Blood. 1995; 85: 3524-31.
15. De Pinho Pessoa BB, Menezes Cavalcante BB, Maia MP et al. Effect of tamoxifen on arterial microvascular anastomosis. Microsurgery. 2007; 27: 286-8.
16. Ceran C, Aksam E, Aksam B et al. Tamoxifen-related thrombosis: an experimental study in rat venous microvascular anastomosis model. Ann Plast Surg. 2017; 78: 213-6.
17. Bĕlohlávek J, Dytrych V, Linhart A et al. Pulmonary embolism, part I: Epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism. Exp Clin Cardiol. 2013; 18: 129-38.
18. Khorana AA, Kuderer NM, Culakova E et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008; 111(10): 4902-7.
19. Lyman GH, Bohlke K, Khorana AA et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol. 2015; 33: 654-6.
20. NCCN Clinical Practice Guidelines in Oncology. Version 2, 2018.
21. Farge D, Frere C, Connors J et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019; 10(20): e566-81.
22. Gerotziafas GT, Taher A, Abdel-Razeq H et al. A predictive score for thrombosis associated with breast, colorectal, lung or ovarian cancer, the prospective COMPASS-cancer associated thrombosis study. Oncologist. 2017; 22: 1222-31.
23. Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer. Update of study BIG 1-98 J Vlin Oncol. 2007; 25: 486-92.
24. van Es N, Di Nisio M, Cesarman G et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica. 2017; 102(9): 1494-501.
25. Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer. 2011; 117(7): 1334-49.
2. Chew HK, Wun T, Harvey D et al. Incidence of Venous Thromboembolism and Its Effect on Survival Among Patients With Common Cancers. Arch Intern Med. 2006; 166(4): 458-64.
3. Brand JS, Hedayati E, Bhoo-Pathy N et al. Time-dependent risk and predictors of venous thromboembolism in breast cancer patients: A population-based cohort study. Cancer. 2017; 123(3): 468-75.
4. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005; 6: 401-10.
5. Braithwaite RS, Chlebowski RT, Lau J et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003; 18(11): 937-47.
6. Metzger Filho O, Giobbie-Hurder A, Mallon E et al. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. J Clin Oncol. 2015; 33(25): 2772-9.
7. Burstein HJ, Temin S, Anderson H et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014; 32(21): 2255-69.
8. Wojtukiewicz MZ, Sierko E. Zakrzepy a nowotwory. In: Windyga J,Pasierski T, Torbicki A (ed). Zakrzepy i zatory. Wyd. I. Wydawnictwo Lekarskie PZWL, Warszawa 2014: 85-105.
9. Wojtukiewicz MZ, Sierko E. Powikłania zakrzepowo zatorowe u chorych na nowotwory. In: Wojtukiewicz MZ, Deptała A (ed). Problemy hematologiczne u chorych na nowotwory. Wyd. I. Termedia, Poznań 2014; 225-50.
10. Cushman M, Costantino JP, Bovill EG et al. Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial. Br J Haematol. 2003; 120: 109-16.
11. Caine YG, Bauer KA, Barzegar S et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost. 1992; 68: 392-5.
12. de Valk-de Roo GW, Stehouwer CD, Meijer P et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol. 1999; 19: 2993-3000.
13. Kessler CM, Szymanski LM, Shamsipour Z et al. Estrogen replacement therapy and coagulation: relationship to lipid and lipoprotein changes. Obstet Gynecol. 1997; 89: 326-31.
14. Zoller B, Garcia de Frutos P, Dahlback B. Evaluation of the relationship between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease. Blood. 1995; 85: 3524-31.
15. De Pinho Pessoa BB, Menezes Cavalcante BB, Maia MP et al. Effect of tamoxifen on arterial microvascular anastomosis. Microsurgery. 2007; 27: 286-8.
16. Ceran C, Aksam E, Aksam B et al. Tamoxifen-related thrombosis: an experimental study in rat venous microvascular anastomosis model. Ann Plast Surg. 2017; 78: 213-6.
17. Bĕlohlávek J, Dytrych V, Linhart A et al. Pulmonary embolism, part I: Epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism. Exp Clin Cardiol. 2013; 18: 129-38.
18. Khorana AA, Kuderer NM, Culakova E et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008; 111(10): 4902-7.
19. Lyman GH, Bohlke K, Khorana AA et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol. 2015; 33: 654-6.
20. NCCN Clinical Practice Guidelines in Oncology. Version 2, 2018.
21. Farge D, Frere C, Connors J et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019; 10(20): e566-81.
22. Gerotziafas GT, Taher A, Abdel-Razeq H et al. A predictive score for thrombosis associated with breast, colorectal, lung or ovarian cancer, the prospective COMPASS-cancer associated thrombosis study. Oncologist. 2017; 22: 1222-31.
23. Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer. Update of study BIG 1-98 J Vlin Oncol. 2007; 25: 486-92.
24. van Es N, Di Nisio M, Cesarman G et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica. 2017; 102(9): 1494-501.
25. Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer. 2011; 117(7): 1334-49.